OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OKYO OKYO Pharma Limited

Market Closed 06-12 16:00:00 EDT

1.52

-0.03

-1.94%

盘后1.52

+0.000.00%

18:19 EDT

High1.56	Low1.42	Vol157.15K
Open1.56	D1 Closing1.55	Amplitude9.03%
Mkt Cap79.77M	Tradable Cap47.66M	Total Shares52.48M
T/O238.77K	T/O Rate0.50%	Tradable Shares31.35M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OKYO","market":"US","secType":"STK","nameCN":"OKYO Pharma Limited","latestPrice":1.52,"timestamp":1781294400000,"preClose":1.55,"halted":0,"volume":157149,"hourTrading":{"tag":"盘后","latestPrice":1.52,"preClose":1.52,"latestTime":"18:19 EDT","volume":6,"amount":9.06,"timestamp":1781302746634,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.019354838709677438,"floatShares":31353600,"shares":52479300,"eps":-0.1114,"marketStatus":"Market Closed","change":-0.03,"latestTime":"06-12 16:00:00 EDT","open":1.56,"high":1.56,"low":1.42,"amount":238771,"amplitude":0.090323,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.1114,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"adrRate":65,"listingDate":1652760000000,"exchange":"NASDAQ","adjPreClose":1.55,"preHourTrading":{"tag":"盘前","latestPrice":1.47,"preClose":1.55,"latestTime":"09:25 EDT","volume":40,"amount":58.8,"timestamp":1781270718516,"change":-0.08,"changeRate":-0.051613,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.52,"preClose":1.52,"latestTime":"18:19 EDT","volume":6,"amount":9.06,"timestamp":1781302746634,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.9529337426233924},"requestUrl":"/m/hq/s/OKYO/wiki","defaultTab":"wiki","newsList":[{"id":"2640921195","title":"OKYO Pharma files Form 3 as director Bernard Denoyer reports beneficial ownership holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2640921195","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640921195?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:28","pubTimestamp":1780442931,"startTime":"0","endTime":"0","summary":"OKYO Pharma director Bernard Denoyer reported holding stock options for 31,890 common shares, with exercise prices spanning $1.46 to $2.13.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDLcbJFh2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640960182","title":"OKYO Pharma files Form 3 for director John P. Brancaccio initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2640960182","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640960182?lang=en_us&edition=fundamental","pubTime":"2026-06-02 06:45","pubTimestamp":1780353936,"startTime":"0","endTime":"0","summary":"OKYO Pharma director John P. Brancaccio reported 30,201 common shares, including stock options for 114,864 shares at $1.46-$2.13.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL2PqGJD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637344324","title":"OKYO Pharma files Form 3 for CEO, director Robert Dempsey beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2637344324","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637344324?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:17","pubTimestamp":1779481024,"startTime":"0","endTime":"0","summary":"OKYO Pharma CEO Robert John Dempsey filed an initial Form 3 disclosing options for 1.6 million common shares exercisable at $2.23, expiring Jan. 2, 2036.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDLb7CSKj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636853742","title":"OKYO Pharma Adds European Eye Disease Expert to Advisory Board as Urcosimod Advances in Neuropathic Corneal Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2636853742","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636853742?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:32","pubTimestamp":1779190335,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has provided an update. On May 19, 2026, OKYO Pharma announced it has expanded its Scientific Advisor...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-adds-european-eye-disease-expert-to-advisory-board-as-urcosimod-advances-in-neuropathic-corneal-pain?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-adds-european-eye-disease-expert-to-advisory-board-as-urcosimod-advances-in-neuropathic-corneal-pain?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPV","OKYO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636385892","title":"OKYO Pharma appoints Marta Sacchetti to scientific advisory board","url":"https://stock-news.laohu8.com/highlight/detail?id=2636385892","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636385892?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:02","pubTimestamp":1779188538,"startTime":"0","endTime":"0","summary":"Sacchetti is an associate professor of ophthalmology at Link University in Rome.She previously served as global head of clinical development for ophthalmology and neurotrophins at Dompé Farmaceutici.The company is developing urcosimod for neuropathic corneal pain, an investigational therapy with FDA Fast Track designation.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL62vTwj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BGHQF748.EUR","BK4588","SG9999014005.SGD","IE00BKPKM429.USD","LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014039.USD","BK4112","IE00BN0W2W23.USD","OKYO","IE00BN0W2V16.EUR","BK4585","LU2210149790.SGD","BK4139","NDAQ","SG9999014021.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636858641","title":"Press Release: OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD","url":"https://stock-news.laohu8.com/highlight/detail?id=2636858641","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636858641?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:00","pubTimestamp":1779188400,"startTime":"0","endTime":"0","summary":"-- Dr. Sacchetti brings international expertise in clinical and. translational research on ocular inflammatory and degenerative disease. -- OKYO's introduction to the broader ophthalmology community at ASCRS drove. LONDON and NEW YORK, May 19, 2026  -- OKYO Pharma Limited , a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain  and for inflammatory eye diseases, today announced the expansion of their Scientific Advisory Board  with the appointment of Marta Sacchetti, MD, PhD. This appointment further enhances the Company's global scientific network with premier European specialists.\"Our world class Scientific Advisory Board is further strengthened by the addition of Marta Sacchetti, MD, PhD,\" said Flavio Mantelli, MD, PhD, Chief Medical Officer of OKYO Pharma. \"Her expertise in neuro-inflammatory corneal diseases brings critical insight into addressing the underlying nerve dysfunction driving neuropathic corneal pa","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MD","OKYO","BK4196","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631590178","title":"OKYO Pharma CEO to present at Eyecelerator conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2631590178","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631590178?lang=en_us&edition=fundamental","pubTime":"2026-04-29 19:01","pubTimestamp":1777460474,"startTime":"0","endTime":"0","summary":"OKYO Pharma CEO Robert Dempsey is scheduled to present at Eyecelerator in Denver on May 1, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL3TpK3Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00B3QW5Z07.USD","BK4585","IE00BN0W2W23.USD","NDAQ","IE00BGHQF748.EUR","SG9999014013.SGD","LU2210150020.SGD","OKYO","BK4112","BK4588","BK4139","SG9999014021.USD","SG9999014039.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","LU0314104364.USD","LU2095319765.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625937439","title":"OKYO Pharma to Showcase Urcosimod Data and Convene Key Advisory Board at 2026 ASCRS Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2625937439","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625937439?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:33","pubTimestamp":1775561605,"startTime":"0","endTime":"0","summary":"An announcement from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. On April 7, 2026, OKYO Pharma announced it will convene a key ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-to-showcase-urcosimod-data-and-convene-key-advisory-board-at-2026-ascrs-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-to-showcase-urcosimod-data-and-convene-key-advisory-board-at-2026-ascrs-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625893258","title":"OKYO Pharma plans new urcosimod trial for neuropathic corneal pain in H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625893258","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625893258?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:01","pubTimestamp":1775559669,"startTime":"0","endTime":"0","summary":"OKYO Pharma scheduled a Scientific Advisory Board meeting during 2026 ASCRS Annual Meeting to review clinical data for lead candidate urcosimod and shape next-stage development plans.Phase 2 proof-of-concept results in neuropathic corneal pain were described as showing encouraging efficacy signals with a favorable safety profile.OKYO plans to initiate next urcosimod clinical trial in first half of 2026, supported by FDA Fast Track status for neuropathic corneal pain.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 07, 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL3DBmFg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620221666","title":"OKYO Pharma Director Boosts Stake as Lead Eye-Pain Drug Advances Toward Phase 2b/3","url":"https://stock-news.laohu8.com/highlight/detail?id=2620221666","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620221666?lang=en_us&edition=fundamental","pubTime":"2026-03-19 22:28","pubTimestamp":1773930503,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) just unveiled an announcement. On March 19, 2026, OKYO Pharma announced that non-executive director J...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-director-boosts-stake-as-lead-eye-pain-drug-advances-toward-phase-2b-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-director-boosts-stake-as-lead-eye-pain-drug-advances-toward-phase-2b-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKYO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620267202","title":"OKYO Pharma director John Brancaccio buys 5,000 shares at USD 1.61","url":"https://stock-news.laohu8.com/highlight/detail?id=2620267202","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620267202?lang=en_us&edition=fundamental","pubTime":"2026-03-19 22:01","pubTimestamp":1773928862,"startTime":"0","endTime":"0","summary":"Non-Executive Director John Brancaccio bought 5,000 OKYO ordinary shares on Nasdaq at USD 1.61.The purchase increased his total holding to 31,201 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLDxnYt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OKYO Pharma director John Brancaccio buys 5,000 shares at USD 1.61","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620024219","title":"Okyo Pharma CDO, director acquire shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620024219","media":"TIPRANKS","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620024219?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:37","pubTimestamp":1773920229,"startTime":"0","endTime":"0","summary":"OKYO Pharma (OKYO) announced it has been informed that Gary Jacob, Chief Development Officer and Director, has acquired 30,980 of the Company’s ord...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/okyo-pharma-cdo-director-acquire-shares-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/okyo-pharma-cdo-director-acquire-shares-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620632228","title":"OKYO Pharma Announces Chief Development Officer and Director Acquires Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620632228","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620632228?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:00","pubTimestamp":1773918000,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, March  19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neurop","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3258842/0/en/OKYO-Pharma-Announces-Chief-Development-Officer-and-Director-Acquires-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620291668","title":"OKYO Pharma Chief Development Officer Gary S. Jacob files Form 3 initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620291668","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620291668?lang=en_us&edition=fundamental","pubTime":"2026-03-19 08:38","pubTimestamp":1773880710,"startTime":"0","endTime":"0","summary":"OKYO Pharma reported an initial statement of beneficial ownership for Gary Jacob, a director and Chief Development Officer. The filing shows he beneficially owned 108,920 shares of common stock. It also lists stock options exercisable for 21,154 shares at a USD 2.13 exercise price. Additional options are shown exercisable for 102,653 shares at a USD 1.6 exercise price.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL10lFXn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620291503","title":"OKYO Pharma Director and 10% Owner Gabriele M Cerrone Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620291503","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620291503?lang=en_us&edition=fundamental","pubTime":"2026-03-19 08:36","pubTimestamp":1773880588,"startTime":"0","endTime":"0","summary":"OKYO Pharma reported an initial statement of beneficial ownership by director and 10% owner Gabriele Cerrone. Cerrone reported direct beneficial ownership of 10.53 million shares of common stock. The date of the event requiring the statement was March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL9s0Bvg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620588452","title":"Okyo Pharma reports results from Phase 2a trial of urcosimod","url":"https://stock-news.laohu8.com/highlight/detail?id=2620588452","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620588452?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:22","pubTimestamp":1773832972,"startTime":"0","endTime":"0","summary":"OKYO Pharma (OKYO) announced new positive findings from an exploratory analysis of patient-reported outcomes in its recently completed Phase 2a tri...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/okyo-pharma-reports-results-from-phase-2a-trial-of-urcosimod-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/okyo-pharma-reports-results-from-phase-2a-trial-of-urcosimod-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620237942","title":"OKYO Pharma reports Phase 2a data showing improved quality-of-life scores with 0.05% urcosimod in neuropathic corneal pain patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2620237942","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620237942?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:02","pubTimestamp":1773831745,"startTime":"0","endTime":"0","summary":"OKYO Pharma reports Phase 2a data showing improved quality-of-life scores with 0.05% urcosimod in neuropathic corneal pain patients. OKYO Pharma reported new findings from an exploratory analysis of patient-reported outcomes in its completed Phase 2a randomized, double-masked, placebo-controlled trial of urcosimod 0.05% for neuropathic corneal pain. The quality-of-life data will be presented in the future at the ARVO 2026 Annual Meeting. In the intent-to-treat population, patients received urcosimod (n=6) or placebo (n=6) for 12 weeks. Reported mean change from baseline included “enjoying life/relationships” of 4.5 with urcosimod versus 0 with placebo on a 0–10 scale. The company also said the Phase 2a results included pain reductions measured by the visual analogue scale and exploratory signals related to corneal nerve structure.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL64RY37:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4112","SG9999014039.USD","NDAQ","SG9999014013.SGD","IE00BN0W2W23.USD","LU0314104364.USD","BK4585","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU2210150020.SGD","LU2095319765.USD","IE00BKPKM429.USD","BK4588","SG9999014005.SGD","SG9999014021.USD","BK4139","OKYO","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613773543","title":"OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2613773543","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613773543?lang=en_us&edition=fundamental","pubTime":"2026-02-24 00:29","pubTimestamp":1771864148,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has shared an update. On February 23, 2026, OKYO Pharma announced that an abstract detailing the firs...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharmas-urcosimod-ncp-data-selected-for-presentation-at-arvo-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharmas-urcosimod-ncp-data-selected-for-presentation-at-arvo-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613733290","title":"OKYO Pharma Abstract Earns Presentation Slot at ARVO 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2613733290","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613733290?lang=en_us&edition=fundamental","pubTime":"2026-02-24 00:00","pubTimestamp":1771862413,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on February 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL4TphnS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4585","SG9999014013.SGD","IE00BKPKM429.USD","LU2095319765.USD","BK4139","BK4112","SG9999014039.USD","LU0314104364.USD","BK4588","SG9999014021.USD","SG9999014005.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD","NDAQ","IE00BGHQF748.EUR","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613735951","title":"OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2613735951","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613735951?lang=en_us&edition=fundamental","pubTime":"2026-02-24 00:00","pubTimestamp":1771862400,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Feb.  23, 2026  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neurop","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/23/3242801/0/en/OKYO-Abstract-Selected-for-Presentation-at-Premier-Global-Ophthalmology-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.okyopharma.com","stockEarnings":[{"period":"1week","weight":-0.0617},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.0843},{"period":"6month","weight":-0.2621},{"period":"1year","weight":-0.3992},{"period":"ytd","weight":-0.2657}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.016922},{"month":2,"riseRate":0.25,"avgChangeRate":-0.048425},{"month":3,"riseRate":0.5,"avgChangeRate":-0.0442},{"month":4,"riseRate":0.5,"avgChangeRate":-0.006578},{"month":5,"riseRate":0.75,"avgChangeRate":0.124495},{"month":6,"riseRate":0.4,"avgChangeRate":-0.033434},{"month":7,"riseRate":1,"avgChangeRate":0.208942},{"month":8,"riseRate":0.5,"avgChangeRate":0.008913},{"month":9,"riseRate":0.25,"avgChangeRate":-0.093671},{"month":10,"riseRate":0.5,"avgChangeRate":0.07182},{"month":11,"riseRate":0,"avgChangeRate":-0.142327},{"month":12,"riseRate":0.75,"avgChangeRate":0.059341}],"exchange":"NASDAQ","name":"OKYO Pharma Limited","nameEN":"OKYO Pharma Limited","securityTypeName":"DR","adrRate":"1:65"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OKYO Pharma Limited(OKYO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OKYO Pharma Limited,OKYO,OKYO Pharma Limited股票,OKYO Pharma Limited股票老虎,OKYO Pharma Limited股票老虎国际,OKYO Pharma Limited行情,OKYO Pharma Limited股票行情,OKYO Pharma Limited股价,OKYO Pharma Limited股市,OKYO Pharma Limited股票价格,OKYO Pharma Limited股票交易,OKYO Pharma Limited股票购买,OKYO Pharma Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OKYO Pharma Limited(OKYO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction